|
RNA Editing Enzyme and Methods of Use Thereof
Inventor:
Kazuko Nishikura
Tech ID:
NK-9480
Description:
The ADAR (adenosine deaminase that acts on RNA) enzyme, previously
known as DRADA, is involved in the RNA editing of glutamate-gated
ion channels and the serotonin-2C receptor. This novel enzyme is
implicated in central nervous system disorders characterized by
abnormal neuronal transmission and intracellular signaling in mammalian
brain such as stroke, schizophrenia, depression, and substance abuse.
Applications and Advantages:
Wistar researchers have identified an ADAR protein that may
be useful for the development of diagnostics and therapeutics for
managing conditions associated with glutamate-gated ion channel
defects or serotonin receptor defects. Potential applications of
ADAR include:
- Screening assays
for novel central nervous system therapeutic
agents,
- Diagnostic assays, using anti-ADAR antibodies
developed at Wistar,
- Generation of therapeutic agents for stroke,
depression, schizophrenia or substance abuse.
Key Words:
Therapeutic, diagnostic, research tool, screening, neurological
disease, psychiatric disease, immunoassay, glutamate, serotonin
Intellectual
Property Status: This technology is protected by US
patents 5,643,778; 5,677,428; and 5,763,174. International patents
are pending.
Licensing
Opportunity: This technology
is available for licensing for development
of diagnostic or therapeutic agents. Additionally,
antibodies to ADAR are available for licensing
for research use.
Contact:
Meryle
J. Melnicoff
Director, Business Development
The Wistar Institute
3601 Spruce Street
Philadelphia, PA 19104
Phone: (215) 898-0049
Fax: (215) 573-2456
melnicoff@wistar.org
Last updated: Aug-02
|
|
